With the aging of the population, death from coronary heart disease (CHD) and stroke has become more prevalent. Cardiovascular disease (CVD) risk factors, such as hypertension, obesity, and diabetes mellitus increase with age as well. Recent secondary-prevention studies have established the positive effect of statins in decreasing the risk of CHD mortality through the lowering of cholesterol. Statins have an excellent safety record, at least with users under age 65, and provide a cheaper alternative to more costly medical options. The most serious side effect associated with their use is myopathy, which is infrequent. Drug interactions have been found with drugs that compete for the same CYP450 isoenzymes as statins. Several drugs have been shown to significantly inhibit the CYP3A4 pathway; in combination with statins such as lovastatin, simvastatin, atorvastatin, and cerivastatin, they have been shown to elevate serum concentrations of these statins, or may increase the risk of myopathy. Alternatively, other drugs can inhibit the CYP2C9 pathway and may elevate serum concentration of fluvastatin. Due to the number of medications the elderly receive, an understanding of the various metabolic pathways is of vital importance to minimize the potential for drug interactions. The elderly population, while at high risk for CVD, is currently undertreated. Statins can effectively lower low-density lipoprotein cholesterol levels and lessen the risk of CVD for this population.
1. Heart and Stroke Statistical Update, American Heart Association, Dallas, 1999
2.
2. Kannel WB. Cardiovascular risk factors in the elderly. Coronary Artery Dis8:565-575, 1997
3.
3. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation89:1329-1448, 1994
4.
4. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study. Arch Intern Med158:1761-1768, 1998
5.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA280:605-613, 1998
6.
6. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation97:1837-1847, 1998
7.
7. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation96:4211-4218, 1997
8.
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med335: 1001-1009, 1996
9.
9. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med129:681-689, 1998
10.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med339:1349-1357, 1998
11.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med333:1301-1307, 1995
12.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA279:1615-1622, 1998
13.
13. Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med320:904-910, 1989
14.
14. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA278:313-321, 1997
15.
15. Crouse JR, III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med157:1305-1310, 1997
16.
16. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care21:179-182, 1998
17.
17. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract47:349-356, 1998
18.
18. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol32:665-672, 1998
19.
19. Lye M, Valacio R, Reckless JPD, et al. Elderly patients with hypercholesterolaemia: A double-blind study of the efficacy, safety, and tolerability of fluvastatin. Coronary Artery Dis9:583-590, 1998
20.
20. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J20:725-741, 1999
21.
21. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol84:1192-1197, 1999
22.
22. Amarenco P, Bogousslavsky J, Callahan A, et al. Effect of atorvastatin compared with placebo on cerebrovascular endpoints in patients with a previous stroke or TIA-the SPARCL study. In: 8th European Stroke Conference, Venice, Italy, 1999
23.
23. LaRosa JC. Effect of lowering LDL-C beyond currently recommended minimum targets-the Treating to New Targets (TNT) study. In: XIIIth International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy, 1998
24.
24. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA265:1145-1151, 1991
25.
25. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med159:593-600, 1999
26.
26. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA260:239-241, 1988
28. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther64:477-483, 1998
29.
29. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther60:54-61, 1996
30.
30. Merck Manual of Geriatrics, Chapter 21 Clinical Pharmacology. Available at: http://www.merck.com/pubs/mm_geriatrics/21x.htm. Accessed January 14, 2000
31.
31. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging14:231-239, 1999
32.
32. Brouwer KLR, Dukes GE, Powell JR. Influence of liver function on drug disposition. In Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3d ed.Applied Therapeutics, Vancouver, WA, pp. 1-59, 1992
33.
33. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy18:84-112, 1998
34.
34. Slaughter RL, Edwards DJ. Recent advances: The cytochrome P450 enzymes. Ann Pharmacother29: 619-624, 1995
35.
35. Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs56:15-23, discussion 33, 1998
36.
36. Boberg M, Angerbauer R, Fey P, et al. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos25:321-331, 1997
37.
37. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications tor metabolic drug interactions. Drug Metab Dispos27:410-416, 1999
38.
38. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother33:1176-1179, 1999
39.
39. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther65:251-261, 1999
40.
40. Regazzi MB, lacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc25:2732-2734, 1993
41.
41. Gruer PJ, Vega JM, Mercuri W, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol84:811-815, 1999
42.
42. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, Yacoub M. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol33:241-246, 1991
43.
43. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation58:42-45, 1994
44.
44. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience. J Clin Pharm Ther24:397-408, 1999
45.
45. Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance?Curr Atheroscl Rep1:14-19, 2000
46.
46. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet34:155-162, 1998
47.
47. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol83:1146-1146, 1999
48.
48. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J90:546-547, 1997
49.
49. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol81:368-369, 1998
50.
50. Summary of safety-related drug labeling changes approved by FDA: January 1999. BAYCOL (cerivastatin Na) tablets. Available at: http://www.fda.gov/medwatch/safety/1999/jan99.htm. Accessed April 6, 2000
51.
51. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med94:13-20, 1993
52.
52. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol82:82U-84U, 1998
53.
53. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol74:149-154, 1994
54.
54. O'Keefe JH, Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol76:480-484, 1995
55.
55. Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy16:419-423, 1996
56.
56. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther64:369-377, 1998
57.
57. Yang B-B, Siedlik PH, Smithers JA, Sedman AJ, Stem RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol. Pharmaceut Res13:S437-S437, 1996
58.
58. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother30:1399-1402, 1996
59.
59. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction (letter). Ann Pharmacother31:790-790, 1997
60.
60. Abramowicz M, ed. Mibefradil-a new calcium-channel blocker. Med Lett Drugs Ther39:103-105, 1997
61.
61. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med154:213-215, 1991
62.
62. Bottorf MB, Behrens DH, Gross A, Markel M. Differences in metabolism of lovastatin and pravastatin as assessed by CYP3A inhibition with erythromycin (abstract). Pharmacotherapy17:184-184, 1997
63.
63. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol46:49-53, 1998
64.
64. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther63:332-341, 1998
65.
65. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole (letter). N Engl J Med333:664-665, 1995
66.
66. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry153:311-320, 1996
67.
67. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis32:111-123, 2000
68.
68. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther66:118-127, 1999
